Binance Coin (BNB) Rebounds 8% After Plunge - Will the Rally Continue?

BNB stages impressive recovery as market watches for sustained momentum

The Bounce Back

Binance Coin defies gravity with an 8% surge following recent market turbulence. The native token of the world's largest crypto exchange proves its resilience once again, leaving traders wondering if this is just a dead cat bounce or the start of something bigger.

Technical Territory

On-chain metrics suggest renewed accumulation patterns emerging among whales. Trading volume spikes 40% during the rebound phase, though skeptics note the rally lacks fundamental catalysts beyond technical oversold conditions.

Exchange Token Dynamics

BNB's performance continues to dance to its own tune—sometimes moving with Bitcoin, other times marching to the beat of Binance's corporate developments. The token's unique position as both utility asset and exchange equity proxy creates fascinating market mechanics that traditional finance analysts still struggle to comprehend.

Market Sentiment Check

Traders remain divided between those seeing value in the dip and others warning of exchange token concentration risks. As one veteran crypto fund manager quipped, 'Nothing makes Wall Street analysts more uncomfortable than an asset that actually gets used for something beyond speculation.'

The Road Ahead

All eyes now turn to whether BNB can consolidate above key support levels. The next 48 hours could determine if this rebound has legs or if traders are just catching falling knives while pretending it's a strategic entry point.

Image source: Getty Images.

Commercial momentum building

(CRSP -2.44%) and(VRTX -1.68%) developed Casgevy, the first gene-editing treatment approved for sickle cell disease and beta-thalassemia, two inherited blood disorders.

Vertex reported $30 million in Casgevy sales in the second quarter of 2025, a sharp uptick from prior quarters, showing the drug is starting to gain traction in the marketplace. Crispr receives 40% of the program's profits through its partnership with Vertex.

By mid-2025, 75 hospitals and clinics worldwide had been cleared to administer Casgevy, and approximately 115 patients had begun the treatment process. As more centers gain experience, patient numbers and sales are expected to grow through 2025 and 2026.

Outside of Casgevy, Crispr is working on several new treatments it fully owns, such as CTX112, a cell-based therapy in early testing for cancer and immune diseases. Results from CTX112 or other key pipeline candidates in late 2025 could provide a boost to the stock if the data show clear progress.

Late-stage catalysts approaching

(NTLA -3.81%) is advancing two CRISPR gene-editing programs toward key readouts. It recently completed enrollment in its Phase 3 study for hereditary angioedema, a rare disease that causes sudden swelling attacks, using a treatment called lonvoguran ziclomeran (NTLA-2002). Topline results are expected in the first half of 2026, with a regulatory filing planned later that year.

Intellia is also pushing forward with its program for ATTR amyloidosis, a disease in which abnormal proteins build up and damage the heart and nerves, using a treatment called nex-z (NTLA-2001). A pivotal trial is underway, and earlier testing showed that a single dose can reduce the TTR protein by approximately 91% in many patients, with data showing sustained reductions over time.

If both programs succeed, Intellia could become one of the first companies to win approval for a single-dose, in vivo CRISPR therapy (where gene editing happens directly inside the body) -- a potential breakthrough that could lift investor expectations and reset how gene-editing companies are valued.

Platform plays with pharma validation

(RXRX -10.24%) runs a drug discovery platform powered by AI and backed by big pharma partnerships such as,, and. In its latest results, the company pulled in $19.2 million in revenue -- primarily from collaborations.

Several clinical trial updates are expected later in 2025. If those trials show its AI-discovered drugs perform well in patients, the market may begin valuing its individual programs more favorably -- and that could unlock significant upside for the stock.

(VKTX -4.00%) is advancing VK2735, a dual GLP-1/GIP agonist, through late-stage development for obesity. In its mid-stage study, the injectable version produced up to 14.7% average weight loss after 13 weeks and is now being tested in a large late-stage trial across obesity and type 2 diabetes populations.

The stock declined in August 2025 after results from the oral formulation showed higher dropout rates caused by gastrointestinal side effects from rapid dose escalation. The findings reflected how the drug was given, not an underlying problem with the compound.

With a slower titration schedule, tolerability could improve meaningfully. Both the injectable and oral versions remain key to Viking's obesity strategy, positioning the company to compete in a market expected to exceed $100 billion in annual sales.